Abstract

Integration of High Throughput ‘Omic Platforms into Antibody Discovery

John Castle, Senior Director, Agenus & 4-Antibody

From antibodies to vaccines to T cells, cancer immunotherapy is extending patient lives. Targeted therapies using immune cell receptors can be targeted to either cancer or immune cells. In pursuit of lead structures, ‘omic technologies are revolutionizing the discovery and development of novel biological lead structures. However, ‘omic platforms are first and foremost data generation instruments that require careful integration into workflows. Here, we demonstrate how we have applied next-generation sequencing, big data, biostatistics, and computational immunology to the discovery and development of novel lead structures.